BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 22609884)

  • 1. Mobilization of PBSCs in poor mobilizers with POEMS syndrome using G-CSF with plerixafor.
    Shimizu N; Sakaida E; Ohwada C; Takeuchi M; Kawaguchi T; Tsukamoto S; Sakai S; Takeda Y; Sugita Y; Yokote K; Iseki T; Isose S; Kanai K; Misawa S; Kuwabara S; Nakaseko C
    Bone Marrow Transplant; 2012 Dec; 47(12):1587-8. PubMed ID: 22609884
    [No Abstract]   [Full Text] [Related]  

  • 2. Differences in Cellular Composition of Peripheral Blood Stem Cell Grafts from Healthy Stem Cell Donors Mobilized with Either Granulocyte Colony-Stimulating Factor (G-CSF) Alone or G-CSF and Plerixafor.
    Teipel R; Oelschlägel U; Wetzko K; Schmiedgen M; Kramer M; Rücker-Braun E; Hölig K; von Bonin M; Heidrich K; Fuchs A; Ordemann R; Kroschinsky F; Bornhäuser M; Hütter G; Schmidt H; Ehninger G; Schetelig J; Heidenreich F
    Biol Blood Marrow Transplant; 2018 Nov; 24(11):2171-2177. PubMed ID: 29935214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of hematopoietic stem cell mobilization strategies including plerixafor in multiple myeloma and lymphoma patients.
    Tichopád A; Vítová V; Kořístek Z; Lysák D
    J Clin Apher; 2013 Dec; 28(6):395-403. PubMed ID: 23922227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patients' outcome after rescue plerixafor administration for autologous stem cell mobilization: a single-center retrospective analysis.
    Spoerl S; Peter R; Wäscher D; Götze K; Verbeek M; Peschel C; Krackhardt AM
    Transfusion; 2017 Jan; 57(1):115-121. PubMed ID: 27859332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing mobilization strategies in difficult-to-mobilize patients: The role of plerixafor.
    Goker H; Etgul S; Buyukasik Y
    Transfus Apher Sci; 2015 Aug; 53(1):23-9. PubMed ID: 26099666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plerixafor (Mozobil).
    Med Lett Drugs Ther; 2010 Apr; 52(1335):27-8. PubMed ID: 20360661
    [No Abstract]   [Full Text] [Related]  

  • 7. How to manage poor mobilizers for high dose chemotherapy and autologous stem cell transplantation?
    Ataca Atilla P; Bakanay Ozturk SM; Demirer T
    Transfus Apher Sci; 2017 Apr; 56(2):190-198. PubMed ID: 28034547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
    Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
    Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics.
    Li J; Hamilton E; Vaughn L; Graiser M; Renfroe H; Lechowicz MJ; Langston A; Prichard JM; Anderson D; Gleason C; Lonial S; Flowers CR; Kaufman JL; Waller EK
    Transfusion; 2011 Oct; 51(10):2175-82. PubMed ID: 21492180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy: a REL (Rete Ematologica Lombarda) experience.
    Arcaini L; Laszlo D; Rizzi S; Balzarotti M; Antoniazzi F; Zilioli VR; Guggiari E; Farina L; Todisco E; Bonfichi M; Alamos SM; Rossi G; Martinelli G; Morra E
    Leuk Res; 2011 Jun; 35(6):712-4. PubMed ID: 21276613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and risk factors of poor mobilization in adult autologous peripheral blood stem cell transplantation: a single-centre experience.
    Lee KH; Jung SK; Kim SJ; Jang JH; Kim K; Kim WS; Jung CW; Kim DW; Kang ES
    Vox Sang; 2014 Nov; 107(4):407-15. PubMed ID: 25130876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful mobilization of PBSCs in a healthy volunteer donor by addition of plerixafor after failure of mobilization with G-CSF alone.
    Neumann T; Krüger WH; Busemann C; Kiefer T; Dölken G
    Bone Marrow Transplant; 2011 May; 46(5):762-3. PubMed ID: 20676150
    [No Abstract]   [Full Text] [Related]  

  • 13. PBSC mobilization in newly diagnosed patients with POEMS syndrome: outcomes and prognostic factors.
    Li J; Zhang W; Duan MH; Jiao L; Zhu TN; Han B; Zhang L; Gan J; Zhou DB
    Bone Marrow Transplant; 2013 Feb; 48(2):233-7. PubMed ID: 22825426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF.
    Chaudhary L; Awan F; Cumpston A; Leadmon S; Watkins K; Tse W; Craig M; Hamadani M
    J Clin Apher; 2013 Oct; 28(5):359-67. PubMed ID: 23765597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plerixafor in poor mobilizers with non-Hodgkin's lymphoma: a multi-center time-motion analysis.
    Mohty M; Azar N; Chabannon C; Le Gouill S; Karlin L; Farina L; Milkovich G; Ostermann H; Glaß B; Noppeney R; Kron F; Kron A; Hübel K
    Bone Marrow Transplant; 2018 Mar; 53(3):246-254. PubMed ID: 29255168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plerixafor in poor stem cell mobilizers: the Belgian Compassionate Use Program.
    Selleslag D; Dierickx D; Breems DA; Huynh P; Van De Velde A; Meers S; Brouwer E; Mertens A
    Acta Clin Belg; 2011; 66(3):200-4. PubMed ID: 21837928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An updated single center experience with plerixafor and granulocyte colony-stimulating factor for stem cell mobilization in light chain amyloidosis.
    Badar T; Dhakal B; Szabo A; Padmanabhan A; Johnson BD; Heidtke S; Esselmann J; Chhabra S; Hamadani M; Hari P; D'Souza A
    J Clin Apher; 2019 Dec; 34(6):686-691. PubMed ID: 31566813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Efficacy of Granulocyte Colony-Stimulating Factor Monotherapy for Peripheral Blood Stem Cell Collection in POEMS Syndrome.
    Muto T; Ohwada C; Takaishi K; Isshiki Y; Nagao Y; Hasegawa N; Kawajiri-Manako C; Togasaki E; Shimizu R; Tsukamoto S; Sakai S; Takeda Y; Mimura N; Takeuchi M; Sakaida E; Misawa S; Shimizu N; Iseki T; Kuwabara S; Nakaseko C
    Biol Blood Marrow Transplant; 2017 Feb; 23(2):361-363. PubMed ID: 27840209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of plerixafor in autologous stem cell mobilization with vinorelbine chemotherapy and granulocyte-colony stimulating factor in patients with myeloma: a phase II study (PAV-trial).
    Schmid A; Friess D; Mansouri Taleghani B; Keller P; Mueller BU; Baerlocher GM; Leibundgut K; Pabst T
    Leuk Lymphoma; 2015 Mar; 56(3):608-14. PubMed ID: 24884311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data.
    Duarte RF; Shaw BE; Marín P; Kottaridis P; Ortiz M; Morante C; Delgado J; Gayoso J; Goterriz R; Martínez-Chamorro C; Mateos-Mazón JJ; Ramírez C; de la Rubia J; Achtereekte H; Gandhi PJ; Douglas KW; Russell NH
    Bone Marrow Transplant; 2011 Jan; 46(1):52-8. PubMed ID: 20305700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.